NASDAQ · VRTX
Vertex Pharmaceuticals Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VRTX: Nov 02, 2026
Vertex Pharmaceuticals Incorporated Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $4.36. The reported EPS for the same quarter last year was $4.22.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $4.36 | $4.71 | $3.72 | 5 |
| Dec 2026 | $4.08 | $4.68 | $3.37 | 7 |
| Mar 2027 | $4.49 | $5.10 | $3.95 | 3 |
| Jun 2027 | $4.65 | $5.11 | $4.03 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks · The Motley Fool- BNK Invest · Oct 29, 10:52 AM EDTNoteworthy ETF Outflows: JEPQ, ISRG, VRTX, REGNLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Nasdaq Equity Premium Income ETF (Symbol: JEPQ) where we have detected an approximate $156.2 million dollar outflow — that's a 0.4% decrea
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Zacks · Oct 28, 9:00 AM EDTRoyalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseRoyalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 28, 8:15 AM EDTAhead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsEvaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- Zacks · Oct 28, 8:00 AM EDTHere is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending StockRecently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- The Motley Fool · Oct 27, 3:45 PM EDTAmgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug RevenueAmgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter.
- Zacks · Oct 27, 10:15 AM EDTVertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
- Zacks · Oct 26, 4:50 PM EDTVertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyIn the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.
- Zacks · Oct 26, 1:33 PM EDTBHC Q3 Earnings Preview: Here's What You Should KnowBausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
- Zacks · Oct 26, 9:00 AM EDTVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Oct 26, 5:05 AM EDTI'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing MoveThe S&P 500 is on track for a 100% gain over three years.
- The Motley Fool · Oct 24, 6:20 PM EDTForget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreOne of CRISPR Therapeutics’ leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Vertex Pharmaceuticals Incorporated from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.